Abstract 2009
Background
The aim of our study was to determine the effect of homologous recombination gene deficiency (HRD) on the effectiveness of platinum chemotherapy and prognosis in patients with pancreatic cancer (PC).
Methods
PubMed and EMBASE database were processed. The search criteria included articles and abstracts till 16.01.2019. Primary outcome was hazard ratio (HR) for overall survival (OS) and 95% confidence interval (CI). Meta-analysis was conducted by «Review Manager» (RevMan) Ver. 5.3.
Results
The request identified 7038 records. A total of 4 studies were included in the meta-analysis and 16 in the systematic review. By the meta-analysis data HRD genotype didn’t affect the prognosis in resectable PC (HR = 1.03, 95% CI 0.46-2.33). By the systemic review average weighted median (AWM) OS for patients with HRD (n = 183) was 34.6 versus 27 months in patients without HRD (n = 1079). For patients who received platinum-based chemotherapy AWM OS was 46.1 months in group with HRD (n = 74) and 36.3 without the HRD (n = 227). For platinum-naive subgroup AWM OS was 24.2 months in HRD (n = 44) and 42.9 in non HRD patients (n = 134). The administration of platinum was associated with more favorable prognosis in HRD patients with resectable PC, but the differences weren`t statistically significant (HR = 0.60, 95% CI 0.36-1.33). For patients with advanced PC AWM OS was 19.8 months in group with HRD (n = 312) versus 15.6 months without HRD (n = 977). In subgroup with platinum, AWM OS was 23.8 and 17.1 months favoring HRD genotype. In subgroup without platinum, AWM OS was 8.3 months vs 12.0 months favoring HRD genotype.
Conclusions
HRD genotype is associated with poor prognosis. But administration of platinum-based chemotherapy can significantly improve the outcome in such a population of pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
This research is conducted under the auspices of the experimental governmental assignment of the Ministry of Health of the Russian Federation and coordinated by the FSBI “Centre for Strategic Planning and Management of Biomedical Health Risks” of the Ministry of Health of the Russian Federation.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5295 - Predictive factors and survival outcomes with stereotactic body radiation therapy in treatment of oligometastases in colorectal cancer
Presenter: Vibhay Pareek
Session: Poster Display session 2
Resources:
Abstract
5887 - Factors of importance in procuring tumoroids from colorectal liver metastasis biopsies for precision medicine.
Presenter: Lars Henrik Jensen
Session: Poster Display session 2
Resources:
Abstract
2196 - FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity
Presenter: Marie-Christine Etienne-Grimaldi
Session: Poster Display session 2
Resources:
Abstract
2859 - Treatments (tx) after progression to first-line FOLFOXIRI + bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and TRIBE-2 studies by GONO.
Presenter: Daniele Rossini
Session: Poster Display session 2
Resources:
Abstract
3888 - Randomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX+FP+ BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study
Presenter: Takeshi Nagasaka
Session: Poster Display session 2
Resources:
Abstract
1065 - Early tumour shrinkage (ETS), depth of response (DpR) and associated survival outcomes in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) classified according to Köhne prognostic category: retrospective analysis of the panitumumab (Pmab) PRIME study
Presenter: Andrea Sartore-Bianchi
Session: Poster Display session 2
Resources:
Abstract
1702 - Randomized phase II trial of CAPOX with planned oxaliplatin stop-and-go strategy as adjuvant chemotherapy after curative resection of colon cancer (CCOG-1302 study)
Presenter: Hiroyuki Yokoyama
Session: Poster Display session 2
Resources:
Abstract
5104 - A metabolomic recurrence score for risk-stratification of elderly patients (pts) with early colorectal cancer (eCRC)
Presenter: Samantha Di Donato
Session: Poster Display session 2
Resources:
Abstract
5285 - RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first line treatment in metastatic colorectal cancer
Presenter: Giulia Martini
Session: Poster Display session 2
Resources:
Abstract
1790 - Impact of prophylactic systemic antibiotics (SA) on outcome of patients (pts) with RAS-wildtype (RAS-wt) metastatic colorectal carcinoma (mCRC) treated with cetuximab-based first-line therapy. Subgroup analysis of the german non-interventional study ERBITAG
Presenter: Stephan Sahm
Session: Poster Display session 2
Resources:
Abstract